Abstract
BackgroundTo study the expression of MK-1 and RegⅣ and to detect their pathological significances in benign and malignant lesions of gallbladder.MethodsThe expression of MK-1 and RegⅣ was detected by immunohistochemical method in paraffin-embedded sections of surgical resected specimens from gallbladder adenocarcinoma (n = 108), peritumoral tissues (n = 46), adenomatous polyp (n = 15), and chronic cholecystitis (n = 35).ResultsThe positive rate of MK-1 or RegⅣ expression was significantly higher in gallbladder adenocarcinoma than that in peritumoral tissues (χ2MK-1 = 18.76, P < 0.01; χ2RegⅣ = 9.92, P < 0.01), denomatous polyp (χ2MK-1 = 9.49, P < 0.01; χ2RegⅣ = 8.59, P < 0.01) and chronic cholecystitis (χ2MK-1 = 24.11, P < 0.01; χ2RegⅣ = 19.24, P < 0.01). The positive cases of MK-1 and/or RegⅣ in the benign lesions showed moderately- or severe-atypical hyperplasia of gallbladder epitheli. The positive rates of MK-1 were significantly higher in the cases of well-differentiated adenocarcinoma, no-metastasis of lymph node, and no-invasiveness of regional tissues than those in the ones of differentiated adenocarcinoma, metastasis of lymph node, and invasiveness of regional tissues in gallbladder adenocarcinoma (P < 0.05 or P < 0.01). On the contrary, the positive rates of RegⅣ were significantly lower in the cases of well-differentiated adenocarcinoma, no-metastasis of lymph node, and no-invasiveness of regional tissues than those in the ones of differentiated adenocarcinoma, metastasis of lymph node, and invasiveness of regional tissues in gallbladder adenocarcinoma (P < 0.05 or P < 0.01). Univariate Kaplan-Meier analysis showed that decreased expression of MK-1 (P = 0.09) or increased expression of RegⅣ (P = 0.003) was associated with decreased overall survival. Multivariate Cox regression analysis showed that decreased expression of MK-1 (P = 0.033) and increased expression of RegⅣ (P = 0.008) was an independent prognostic predictor in gallbladder adenocarcinoma.ConclusionsThe expression of MK-1 and/or RegⅣ might be closely related to the carcinogenesis, clinical biological behaviors, and prognosis of gallbladder adenocarcinoma.
Highlights
MK-1, known as Ep-CAM, is a type-I transmembrane protein with cell adhesion activity expressed on normal epithelial cells of various tissues including stomach, colon, pancreas, lung, breast and ovary
MK1 and RegIV expression is associated with the clinicopathological characters of adenocarcinoma In adenocarcinomas that were highly differentiated, with tumor diameter < 2 cm, with no lymph node metastasis and no peritissue invasion, MK-1 positive expression rate was significantly higher than those that were moderately- or low-differentiated, with tumor maximum diameter ≥ 2 cm, with lymph node metastasis and peritissue invasion (P < 0.05)
The expression of Relationship between MK-1 and RegIV expression and the lifetime of patients with gall bladder adenocarcinoma According to survey by mail or phone (2 years), we got 67 profiles from the 108 gallbladder adenocarcinoma, 20 of them survived more than or equal to 1 year after surgery, 47 of them had less than 1 year life cycle, and mean life cycle was 9.6 ± 5.2 months
Summary
MK-1, known as Ep-CAM, is a type-I transmembrane protein with cell adhesion activity expressed on normal epithelial cells of various tissues including stomach, colon, pancreas, lung, breast and ovary. RegIV, a member of the regenerating gene family, is involved in digestive tract malignancies, including the stomach, colorectum, and pancreas, as well as in benign diseases such as ulcerative colitis [6,7,8,9,10,11]. No study on the expression of RegIV in gallbladder adenocarcinoma has been published. We studied the expression of MK-1 and RegIV in various benign and malignant lesions of gallbladder, and evaluated their prognostic usefulness. To study the expression of MK-1 and RegIV and to detect their pathological significances in benign and malignant lesions of gallbladder
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
